Navigation Links
Milnacipran in Medical News

Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran

NEW YORK and SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ), and Cypress Bioscience, Inc. (Nasdaq: CYPB ) will host a webcast to discuss milnacipran clinical data being presented at the American College of Rheumatology annual conference. The webcast, which...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)

...he symptoms of fibromyalgia. Savella will be marketed by Forest and its licensor, Cypress Bioscience. Pierre Fabre, who originally developed and sells milnacipran outside the U.S., licensed the rights for North America to Cypress Bioscience. Important Safety Information Savella is a selective seroto...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)

...eople in the United States. Savella will be marketed by Forest and its licensor, Cypress Bioscience. Pierre Fabre, who originally developed and sells milnacipran outside the U.S., licensed the rights for North America to Cypress Bioscience. Important Safety Information Savella is a selective seroto...

Zoloft, Lexapro the Best of Newer Antidepressants

...d in the trials were bupropion (Wellbutrin/Zyban), citalopram (Celexa), duloxetine (Cymbalta), escitalopram, fluoxetine (Prozac), fluvoxamine (Luvox), milnacipran (Savella), mirtazapine (Remeron), paroxetine (Paxil), reboxetine (Edronax/Vestra), sertraline, and venlafaxine (Effexor). Based on their analysis, ...

Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia

... analysis." "This approval is crucial for Pierre Fabre Laboratories as milnacipran is one of the flagship products of our portfolio and represents another pro...ensor, Cypress Bioscience. Pierre Fabre, who originally developed and sells milnacipran outside the U.S., licensed the rights for North America to Cypress Bioscien...

Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment

...nt of chronic constipation and constipation predominant irritable bowel syndrome; RGH-188 for the treatment of schizophrenia and bipolar disorder; and milnacipran for the treatment of fibromyalgia. In addition, the Company will support a significant Phase IV post-marketing program in support of Bystolic. These d...

Scientific poster abstracts from the 24th annual meeting of the American Academy of Pain Medicine

...notide to Predict Its Pump Infusion Effect 163 milnacipran Efficacy in the Treatment of Fibromyalgia Syndrome... Report 172 One-Year Durability of Response to milnacipran Treatment for Fibromyalgia 173 Cognitive Compl...f Visceral Pain 179 The Efficacy and Safety of milnacipran in the Treatment of Fibromyalgia 180 Lacosamid...
Milnacipran in Medical Technology

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia

NEW YORK and SAN DIEGO, Dec. 8, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) today announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for th...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome

NEW YORK, May 22, 2007 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and Cypress Bioscience, Inc. today announced that preliminary top-line results from a 1,196 patient randomized, three month, double-blind, placebo-controlled pivotal Phase III study demonstrate statistically significant the...

Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show

...ORK, Nov. 8 /PRNewswire/ -- Total daily dosages of milnacipran 100 mg and 200 mg demonstrated statistically signi... meeting in Boston, MA. The therapeutic effects of milnacipran among responders in a six-month study were sustain...nsion study showed that the therapeutic effects of milnacipran were sustained for up to one year of therapy. "Be...
Milnacipran in Biological Technology

Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome

NEW YORK and SAN DIEGO, Dec. 31 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) announced that they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for milnacipran, a unique dual...

US Neuropathic Pain Market Value Doubles to $5 Billion by 2018

...t 5 years due to penetration of the market for fibromyalgia. Two yet to be launched products, Forest Laboratories/Cypress Biosciences's antidepressant milnacipran and Schwarz Pharma's sodium ion channel antagonist/CRMP2 modulator lacosamide (Vimpat), will compete for market share as well as provide the benefit o...
Other Tags
(Date:9/3/2015)... , ... September 03, 2015 , ... TransPack Toon gives ... Users can choose from wipes and framing transitions in 30 different styles. Presets range ... for Final Cut Pro X. , TransPack Toon features 90 cartoon transitions from 30 ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... for the Academy of Integrative Health & Medicine (AIHM) Interprofessional Fellowship in Integrative ... Tieraona Low Dog, MD, an internationally renowned educator, physician and thought leader in ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... Indiana University, Indianapolis, have chosen Center for Hospice Care (CHC) for physician ... will train at CHC as part of fulfilling their requirements for obtaining national ...
(Date:9/3/2015)... ... September 03, 2015 , ... BedJet released a new version of its ... on Kickstarter. Today the BedJet v2 pre-order campaign blazed past the $1 ... successful campaigns ever on crowdfunding giant Kickstarter. , Simple to use and beautifully designed, ...
(Date:9/3/2015)... ... September 03, 2015 , ... Silverado next week lays the ... Drive in Bellingham, Washington. Silverado Bellingham, a 41,000 square foot, single-story community, is ... up to 80 people living with Alzheimer’s, dementia and other memory-impairing conditions. ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
Other Contents